2025: A Year of breakthroughs Reshapes Heart Failure Care
A wave of advancements in 2025 has dramatically altered the landscape of heart failure (HF) treatment adn prevention, from landmark guideline shifts to a surge of FDA approvals. The editorial team at HCPLive has compiled a review of the 12 most impactful headlines from the past year, highlighting a renewed focus on proactive care and innovative therapies.
A Paradigm Shift Towards Prevention
The year began with a call to action, as the Heart Failure Society of America (HFSA) and the American Society for Preventive Cardiology (ASPC) jointly emphasized the critical need to prioritize prevention in HF care. Released on August 13, 2025, the statement urged clinicians to actively identify risk factors – including inflammation – and implement holistic strategies encompassing improved sleep, regular exercise, weight management, and control of blood pressure, cholesterol, and glycemia. The document outlined four key components of HF prevention: early risk identification, holistic care, proven therapies, and system-wide change.
FDA Approvals Drive Innovation
The US Food and Drug Administration (FDA) played a pivotal role in advancing HF care throughout 2025, approving several novel therapies and expanding the indications of existing ones.
- Mavacamten Label Update (April 17, 2025): The FDA streamlined echo monitoring requirements for adults with obstructive hypertrophic cardiomyopathy.
- Omecamtiv Mecarbil Approval (May 22, 2025): Omecamtiv mecarbil received FDA approval for the treatment of symptomatic chronic heart failure with reduced ejection fraction (hfref), offering a novel mechanism of action by directly activating cardiac myosin.
- intravenous Pemafibrent Alternative (June 15, 2025): A new formulation of pemafibrent, administered subcutaneously, demonstrated equivalent efficacy to intravenous loop diuretics in managing fluid overload associated with HF, demonstrating equivalent efficacy with a faster time to maximum concentration.
Trial Insights Refine Treatment Strategies
Beyond FDA approvals, key trial results provided further insights into optimizing HF management.
- Finerenone and Diuretic Intensification (February 2025): A secondary analysis of the FINEARTS-HF trial revealed that finerenone could prevent the need for outpatient oral diuretic intensification in patients with mildly reduced or preserved ejection fraction, reinforcing its potential to mitigate worsening HF events.
- DAPA-EAT: DapagliflozinS Impact on Epicardial Adipose Tissue: Presented at the American Heart Association’s Scientific Sessions, the DAPA-EAT trial highlighted dapagliflozin’s ability to reduce epicardial adipose tissue (EAT), left ventricular myocardial fibrosis, and improve diastolic filling dynamics in patients with asymptomatic HF. Dapagliflozin reduced EAT by 15.6 mL compared to a 9.6 mL reduction in the control group.
- SURPASS-CVOT: Tirzepatide Shows Promise (July 31, 2025): the SURPASS-CVOT trial demonstrated that tirzepatide was non-inferior to dulaglutide in reducing major adverse cardiovascular events in adults with type 2 diabetes and atherosclerotic cardiovascular disease, with additional benefits observed in A1C, weight, renal function, and all-cause mortality.
Expanding the Conversation: Podcasts and Expert analysis
HCPLive further explored these advancements through a series of podcasts and feature content. A 7-part special report delved into the HFSA/ASPC prevention statement, emphasizing the need to unify preventive cardiology and HF care. Experts discussed the potential of vericiguat as a mortality-reducing therapy in ambulatory HFrEF, and debated the merits of oral diuretic intensification as a clinical trial endpoint. Additionally, the novel concept of a polypill approach to HFrEF – combining metoprolol succinate, spironolactone, and empagliflozin – was explored, with the POLY-HF trial demonstrating a 3.4% greater improvement in LVEF and a 50% reduction in recurrent HF hospitalizations in patients receiving the polypill.
The year 2025 marked a period of considerable progress in heart failure care,driven by a proactive shift towards prevention,innovative FDA approvals,and insightful clinical trial data. These advancements collectively offer renewed hope for improving outcomes and enhancing the quality of life for individuals living with this complex condition.
